---
title: "Astrazeneca's new triple-antibody drug has been approved for clinical trials in China, intended for the treatment of systemic lupus erythematosus and other conditions"
description: "On April 2, the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China announced that AstraZeneca's Class 1 new drug AZD5492 has been approved for two new clinical t"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/234231161.md"
published_at: "2025-04-02T13:19:02.000Z"
---

# Astrazeneca's new triple-antibody drug has been approved for clinical trials in China, intended for the treatment of systemic lupus erythematosus and other conditions

> On April 2, the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China announced that AstraZeneca's Class 1 new drug AZD5492 has been approved for two new clinical trial implicit licenses in China, intended for the treatment of systemic lupus erythematosus and idiopathic inflammatory myopathy. Public information shows that this is a CD20×TCR×CD8 trispecific antibody, guided by a CD8 T cell connector (TCE). The product was first approved for clinical use in China in October 2024, with indications for relapsed or refractory B-cell malignancies. AZD5492 is an asymmetric trispecific monoclonal IgG1 antibody that contains two anti-CD20 Fab domains, one VHH domain that binds to TCR, and one VHH domain that binds to the CD8 co-receptor. Public information indicates that due to the specific action of anti-CD20 antibodies on B cells, they are widely developed for the treatment of B cell-related diseases, including non-Hodgkin lymphoma and other B cell malignancies, as well as autoimmune diseases such as systemic lupus erythematosus, systemic sclerosis, and idiopathic inflammatory myopathy

According to the Zhitong Finance APP, on April 2, the official website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China announced that Astrazeneca (AZN.US) has received implicit approval for two new clinical trials for its Class 1 new drug AZD5492 in China, intended for the treatment of systemic lupus erythematosus and idiopathic inflammatory myopathy. Public information shows that this is a CD20×TCR×CD8 trispecific antibody, which is a T cell engager (TCE) guided by CD8. The product is expected to be approved for clinical use in China in October 2024, with indications for relapsed or refractory B-cell malignancies.

![image.png](https://imageproxy.pbkrs.com/https://img.zhitongcaijing.com/image/20250402/1743599778650348.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg)

AZD5492 is an asymmetric trispecific monoclonal IgG1 antibody that contains two anti-CD20 Fab domains, a VHH domain that binds to TCR, and a VHH domain that binds to the CD8 co-receptor. Public information indicates that due to the specific action of anti-CD20 antibodies on B cells, they are widely developed and applied in the treatment of B cell-related diseases, including non-Hodgkin lymphoma and other B cell malignancies, as well as autoimmune diseases such as systemic lupus erythematosus, systemic sclerosis, and idiopathic inflammatory myopathy

### Related Stocks

- [AZN.US - AstraZeneca](https://longbridge.com/en/quote/AZN.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Trump Strikes Again: AstraZeneca's Surprise Drug Deal Could Shake Big Pharma's Global Pricing Power | AstraZeneca has reached a drug-pricing deal with President Trump to reduce Medicaid drug prices, potentially reshaping B | [Link](https://longbridge.com/en/news/260941568.md) |
| ANALYSIS-AstraZeneca's US listing may pull other firms from London in its wake | AstraZeneca's decision to upgrade its U.S. listing while retaining its London presence may influence other UK firms to c | [Link](https://longbridge.com/en/news/259563996.md) |
| ConocoPhillips considers selling Permian assets worth $2 billion, Bloomberg News reports | Feb 20 (Reuters) - ConocoPhillipsis exploring a sale of some of its Permian Basin assets as part of a broader streamlini | [Link](https://longbridge.com/en/news/276478732.md) |
| IronBridge Private Wealth LLC Has $905,000 Holdings in Apple Inc. $AAPL | IronBridge Private Wealth LLC reduced its stake in Apple Inc. (NASDAQ:AAPL) by 77.3% in Q3, holding 3,555 shares valued  | [Link](https://longbridge.com/en/news/276436345.md) |
| Financial Advocates Investment Management Lowers Stock Position in Meta Platforms, Inc. $META | Financial Advocates Investment Management reduced its stake in Meta Platforms, Inc. by 66.7% in Q3, now holding 2,343 sh | [Link](https://longbridge.com/en/news/276432394.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.